Selexis SA

Plan-les-Ouates, Switzerland

Selexis SA

Plan-les-Ouates, Switzerland
SEARCH FILTERS
Time filter
Source Type

Patent
Selexis S.A. | Date: 2017-07-12

The invention discloses a method for selecting cells depending on their level of displaying and preferably secreting a protein of interest from a population of heterogeneously expressing cells, comprising: (a) contacting said cells with magnetic beads coated with an affinity group to the said cells, (b) mixing the said magnetic beads with the cells to capture the cells displaying/secreting the protein of interest, (c) performing at least one washing step to remove the non-captured cells, and (d) recovering the cells to which that magnetic beads have bound.


Selexis SA and OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™. The agreement builds upon previous collaboration between the two companies as announced in November 2016 and is designed to support the advancement of the clinical development of OSE’s interleukin receptor 7 antagonist, OSE-127 (Effi-7), under development as a potential treatment for inflammatory bowel diseases, such as ulcerative colitis. “Based on the successful completion of our initial work on the OSE-127 program, we are pleased to broaden the scope of our collaboration with OSE Immunotherapeutics,” said Marco Bocci, PhD, DPharm, Selexis vice president, licensing and business development. “The broad applicability of our technology, coupled with our robust cell lines, provides our partners with the opportunity to continue working with us long-term across their drug development cycles. We look forward to helping OSE Immunotherapeutics realize the full potential of OSE-127.” “We are pleased to advance our collaboration with Selexis with the initiation of a key step for our immunotherapy OSE-127 towards the clinical stage and its development in ulcerative colitis,” said Dominique Costantini, chief executive officer of OSE Immunotherapeutics. OSE-127 is a humanized monoclonal antibody targeting the CD127 receptor (the alpha chain of the Interleukin 7 receptor (IL-7R)). It induces a powerful antagonist effect for better control of the pathogenic T lymphocytes involved in autoimmune diseases. The strategy of blocking the IL-7 has demonstrated efficacy in restoring the impaired immune balance in autoimmune diseases of the bowel in several preclinical models, such as ulcerative colitis. Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies of activation and regulation in immuno-oncology, autoimmune diseases and transplantation. The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical Phase 3 registration trials to R&D: The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter into global agreements at different stages of development with major pharmaceutical players. Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60 percent of treatments against less than 3 percent at present* and the projected market is estimated at $67 billion in 2018.** There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales of towards $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system. More information: http://ose-immuno.com About Selexis SA Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 95 partners worldwide, more than 75 biologic drug development programs and three commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com. This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 28 April 2017 under the number R.17-038, including the annual financial report for the fiscal year 2016, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.


GENEVA & NANTES, France--(BUSINESS WIRE)--Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™. The agreement builds upon previous collaboration between the two companies as announced in November 2016 and is designed to support the advancement of the clinical development of OSE’s interleukin receptor 7 antagonist, OSE-127 (Effi-7), under development as a potential treatment for inflammatory bowel diseases, such as ulcerative colitis. “Based on the successful completion of our initial work on the OSE-127 program, we are pleased to broaden the scope of our collaboration with OSE Immunotherapeutics,” said Marco Bocci, PhD, DPharm, Selexis vice president, licensing and business development. “The broad applicability of our technology, coupled with our robust cell lines, provides our partners with the opportunity to continue working with us long-term across their drug development cycles. We look forward to helping OSE Immunotherapeutics realize the full potential of OSE-127.” “We are pleased to advance our collaboration with Selexis with the initiation of a key step for our immunotherapy OSE-127 towards the clinical stage and its development in ulcerative colitis,” said Dominique Costantini, chief executive officer of OSE Immunotherapeutics. OSE-127 is a humanized monoclonal antibody targeting the CD127 receptor (the alpha chain of the Interleukin 7 receptor (IL-7R)). It induces a powerful antagonist effect for better control of the pathogenic T lymphocytes involved in autoimmune diseases. The strategy of blocking the IL-7 has demonstrated efficacy in restoring the impaired immune balance in autoimmune diseases of the bowel in several preclinical models, such as ulcerative colitis. Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies of activation and regulation in immuno-oncology, autoimmune diseases and transplantation. The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical Phase 3 registration trials to R&D: The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter into global agreements at different stages of development with major pharmaceutical players. Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60 percent of treatments against less than 3 percent at present* and the projected market is estimated at $67 billion in 2018.** There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales of towards $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system. More information: http://ose-immuno.com Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 95 partners worldwide, more than 75 biologic drug development programs and three commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com. This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 28 April 2017 under the number R.17-038, including the annual financial report for the fiscal year 2016, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.


Selexis SA et OSE Immunotherapeutics SA (Paris:OSE) (ISIN : FR0012127173 ; Mnémo : OSE), annoncent aujourd’hui la signature d’un contrat de licence commerciale qui donnera à OSE Immunotherapeutics l’accès à des banques de cellules de recherche (Research Cell Banks) via la plateforme SUREtechnology™ de Selexis. La mise en place de cet accord fait suite à une première collaboration conclue entre les deux sociétés en novembre 2016, et vise à accompagner l’avancement du développement clinique d’OSE-127 (Effi-7), antagoniste du récepteur à l’interleukine-7, dans les maladies inflammatoires de l’intestin comme la rectocolite hémorragique. À PROPOS D’OSE IMMUNOTHERAPEUTICS Notre ambition est de devenir l’un des leaders mondiaux en immunothérapie d’activation et de régulation OSE Immunotherapeutics est une société de biotechnologie spécialisée dans l’activation et la régulation immunitaire en immuno-oncologie, dans les maladies auto-immunes et en transplantation. La société dispose d’un portefeuille équilibré de premier plan, avec un profil de risque diversifié, allant de la phase clinique d’enregistrement à la R&D : Il existe plus de 80 maladies auto-immunes qui représentent un marché important intégrant des acteurs majeurs de l’industrie pharmaceutique, avec des chiffres d’affaires supérieurs à 10 milliards d’euros pour les principaux produits. Le besoin médical reste à ce jour largement insatisfait et nécessite la mise à disposition de nouveaux produits de régulation du système immunitaire innovants et adaptés. Plus d’informations sur http://ose-immuno.com Cliquez et suivez-nous sur Twitter et Linkedln À PROPOS DE SELEXIS SA Selexis SA est une société pionnière dans le domaine des sciences de la vie et un leader mondial dans la production de lignées cellulaires de mammifères (« suspension-adapted » CHO-K1), proposant une technologie brevetée unique et l'expertise nécessaire pour transformer l'innovation scientifique en médicaments pour les patients. La plateforme SUREtechnology™ de Selexis facilite la production rapide, stable et rentable de toutes protéines recombinantes et permet une intégration du continuum de bioproduction, de la découverte à la commercialisation. Avec plus de 95 partenaires dans le monde, plus de 75 programmes de développement de produits biologiques et trois produits commerciaux utilisant ses lignées cellulaires, Selexis a pour mission de permettre aux scientifiques et aux sociétés biopharmaceutiques du monde entier de réaliser le plein potentiel de leurs recherches. Plus d'informations sur www.selexis.com Déclarations prospectives Ce communiqué contient de manière implicite ou expresse des informations et déclarations pouvant être considérées comme prospectives concernant OSE Immunotherapeutics. Elles ne constituent pas des faits historiquement avérés. Ces informations et déclarations comprennent des projections financières reposant sur des hypothèses ou suppositions formulées par les dirigeants d’OSE Immunotherapeutics à la lumière de leur expérience et de leur perception des tendances historiques, de la situation économique et sectorielle actuelle, de développements futurs et d’autres facteurs qu’ils jugent opportuns. Ces déclarations prospectives peuvent être souvent identifiées par l’usage du conditionnel et par les verbes « s’attendre à », « anticiper », « croire », « planifier » ou « estimer » et leurs déclinaisons et conjugaisons ainsi que par d’autres termes similaires. Bien que la direction d’OSE Immunotherapeutics estime que ces déclarations prospectives sont raisonnables, les actionnaires d’OSE Immunotherapeutics et les autres investisseurs sont alertés sur le fait que leur réalisation est sujette par nature à de nombreux risques connus ou non et incertitudes, difficilement prévisibles et en dehors du contrôle d’OSE Immunotherapeutics. Ces risques peuvent impliquer que les résultats réels et développements effectivement réalisés diffèrent significativement de ceux indiqués ou induits dans ces déclarations prospectives. Ces risques comprennent notamment ceux développés ou identifiés dans les documents publics déposés par OSE Immunotherapeutics auprès de l’AMF. De telles déclarations prospectives ne constituent en rien la garantie de performances à venir. Ce communiqué n’inclut que des éléments résumés et doit être lu avec le Document de Référence d’OSE Immunotherapeutics, enregistré par l’AMF le 28 avril 2017 sous le n° R.17-038, incluant le rapport financier annuel 2016, disponible sur le site internet d’OSE Immunotherapeutics. OSE Immunotherapeutics ne prend aucun engagement de mettre à jour les informations et déclarations prospectives à l’exception de ce qui serait requis par les lois et règlements applicables.


GENEVA--(BUSINESS WIRE)--Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today the dedication of a new, state-of-the-art laboratory and corporate headquarters in Geneva, Switzerland. Selexis CEO and Chairman Igor Fisch, PhD, officially introduced the new space to a host of Swiss-based biotech and government dignitaries last night during a grand opening and ribbon-cutting event. “This move marks a tremendous accomplishment for Selexis, which was founded 15 years ago with a small office in Geneva while the laboratory was based at the University of Lausanne with just one scientist and a seed investment of one hundred thousand Swiss Francs. Now, we have dedicated a new facility worthy of incredible scientists and professionals who occupy it. Our new headquarters reflect our commitment to Geneva and to our status as the world-class leaders (scientific and technology) in the cell line development market as well as in biologic drug discovery,” said Dr. Fisch. “We’re very proud of what we have accomplished here in such a fast-growing Swiss biotech region, and we look forward to contributing further to the economic vitality of the biotech community in Geneva as our technology fosters the advancement of important biologic drugs and vaccines for patients facing diseases as diverse as cancer and HIV.” The new R&D facility houses Selexis’ proprietary SUREtechnology™ Platform, which facilitates the rapid, stable, and cost-effective generation of cell lines producing virtually any recombinant protein. The platform provides seamless integration of the biologics development continuum, spanning discovery to commercialization. Additionally, the building will serve as headquarters for Selexis’ corporate and scientific leadership teams. The facility, located at Plan les Ouates, a suburb of Geneva, Switzerland, has tripled its capacity to meet partner demands. “We are proud to see Selexis continuing its rich history of growth and investment in operations here in Geneva. We congratulate Dr. Fisch and his team on their impressive new facility,” said Pierre Maudet, Conseiller d’Etat for Geneva. “The important work that Selexis is doing right here will help improve the lives of million of people across the globe, and we look forward to their continued success.” In addition to Dr. Fisch and Mr. Maudet, special guests at the ribbon-cutting ceremony included Fabienne Monbaron, Mayor of Plan-les-Ouates, and Dr. Bettina Ernst, a board member of the Swiss Biotech Association. Today, Selexis has more than 30 employees and 95 partners worldwide. The company’s technology has fostered the advancement of more than 75 biologic drug development programs and three commercially available drugs. In January of 2015, Selexis reached an important milestone with the approval of the first therapeutic biologic generated on its platform. Since then, Selexis has had several seminal announcements, including: Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 95 partners worldwide, more than 75 biologic drug development programs and three commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.


A purified and isolated DNA sequence has protein production increasing activity. Said DNA sequence comprises at least one bent DNA element, and at least one binding site for a DNA binding protein. It is a MAR nucleotide with the sequence SEQ ID No 24, a sequence complementary thereof, or a sequence having at least 70% identity with said sequence. Advantageously the bent DNA element contains at least 10% of dinucleotide TA, and/or at least 12% of dinucleotide AT on a stretch of 100 contiguous base pairs.


A purified and isolated DNA sequence has protein production increasing activity. Said DNA sequence comprises at least one bent DNA element, and at least one binding site for a DNA binding protein. It is a MAR nucleotide with the sequence SEQ lD No 27, a sequence complementary thereof, or a sequence having at least 70% identity with said sequence. Advantageously the bent DNA element contains at least 10% of dinucleotide TA, and/or at least 12% of dinucleotide AT on a stretch of 100 contiguous base pairs.


A purified and isolated DNA sequence has protein production increasing activity. Said DNA sequence comprises at least one bent DNA element, and at least one binding site for a DNA binding protein. It is a MAR nucleotide with the sequence SEQ ID No 26, a sequence complementary thereof, or a sequence having at least 70% identity with said sequence. Advantageously the bent DNA element contains at least 10% of dinucleotide TA, and/or at least 12% of dinucleotide AT on a stretch of 100 contiguous base pairs.


The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.


Patent
Selexis S.A. | Date: 2014-02-01

Disclosed are constructs and methods for expressing DNAs of interest in particular in non-primate eukaryotic host cells that display advantages with regard quantity and quality of expression including high stability of expression and, if appropriate, transport of the expression product out of the cell.

Loading Selexis SA collaborators
Loading Selexis SA collaborators